Brentuximab vedotin begins new trial for Hodgkin's lymphoma
This article was originally published in Scrip
Seattle Genetics and Takeda have begun a Phase III trial with the antibody-drug conjugate brentuximab vedotin in patients at high risk of residual Hodgkin's lymphoma (HL) following autologous stem cell transplant (ASCT).
You may also be interested in...
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.